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Background: Fractional exhaled NO (Fe,NO) has yielded inconsistent results in COPD.
Measuring exhaled NO at multiple flow rates however, allows to dissect exhaled NO in an
alveolar (CAlv,NO) and bronchial (J’aw,NO) fraction, which are claimed to better reflect the
bronchial and alveolar inflammation in COPD. We examined whether the use of Fe,NO, CAlv,NO
and J’aw,NO may contribute to the clinical diagnosis of COPD.
Methods: One hundred and fifty one patients were included in this caseecontrol design: 28
healthy nonsmokers, 39 healthy smokers, 55 COPD nonsmokers and 29 COPD smokers. Prior
to spirometry, exhaled NO was measured at three different flow rates (50, 100 and
200 ml/s; NIOX-FLEX) from which Fe,NO, CAlv,NO and J’aw,NO were calculated.
Results: Mean Fe,NO, mean CAlv,NO and mean J’aw,NO of healthy individuals were not
significantly different from COPD patients and none of these variables correlated with FEV1.
In both healthy and COPD patients, current smoking significantly reduced Fe,NO, J’aw,NO
and CAlv,NO. Multivariate analysis demonstrated that in contrast to gender, age, BMI, GOLD
stage and the use of inhaled corticosteroids, current smoking was the only variable affecting
CAlv,NO. (pZ 0.0115)
Conclusion: We conclude that similar to single breath exhaled NO, exhaled NO at different flow
rates does not contribute to the diagnosis of COPD in standard respiratory practice.
ª 2010 Elsevier Ltd. All rights reserved.33 01 36; fax: þ32 16 34 71
uleuven.be (A. Lehouck).
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow obstruction and is a major cause of
chronic morbidity and mortality worldwide.1 Despite the
need for more early diagnosis and the possibility to perform.
Alveolar exhaled NO in COPD 1021diagnostic spirometry in primary care, COPD is often under-
or misdiagnosed.2 Moreover, once the diagnosis of COPD is
established by post-bronchodilator spirometry, a large
heterogeneity in phenotypic presentation still exists
beyond a given level of FEV1.
3 Different phenotypes will be
treated differently in the nearby future and biomarkers
which may attribute to this differentiation are manda-
tory.4,5 As COPD is an inflammatory disease of the airways,
exhaled biomarkers which reflect airway inflammation and
correlate with disease severity may therefore help to
improve monitoring and treatment of COPD.
In the last 10 years a lot of interest has gone to exhaled
nitric oxide (eNO) as a biomarker for airway inflammation.
Nitric oxide (NO) is biosynthesized endogenously from
L-arginine and oxygen by various isoforms of the enzyme NO
synthase (NOS). NO can have numerous biological effects,
including neutrotransmission, vasodilation and immuno-
regulation. In COPD patients, NOS expression is elevated in
neutrophils and macrophages within the lumen and airway
wall.6 In addition, it is also shown that severe COPD
patients have higher numbers of nitrotyrosine and myelo-
peroxidase positive cells than healthy subjects and mild/
moderate COPD patients.7
In asthma patients, measuring fractional exhaled NO
(Fe,NO) is a simple, noninvasive method for asthma diag-
nosis and monitoring.8 Compared to healthy controls,
patients with asthma have exhaled NO levels which corre-
late with sputum eosinophil counts and are associated with
a positive response to steroid treatment.9 Although the
measurement of exhaled NO is useful in the initial work-up
of asthma, a recent large prospective randomized
controlled trial in 546 patients showed no benefit on
asthma control by Fe,NO monitoring compared to conven-
tional follow-up. It even resulted in higher doses of inhaled
steroids. In COPD the application of fractional exhaled NO is
clearly not recommended as different studies have given
very inconsistent results. However, since small airways and
lung parenchyma are the predominant sites of inflammationTable 1 Subject demographics.
Healthy ex-smokers Hea
Subjects 28 39
Age (years) 63 5 63
Gender (% male) 93% 77%
BMI 27 3 27
GOLD (1/2/3/4) NA NA
Pack year history 47 27 45
FEV1 (L) 3.3 0.6 3.1
FEV1 (% pred) 101 15 100
FVC (L) 4.4 0.8 4.1
FVC (% pred) 110 15 110
FEV1/FVC (% pred) 73 3 73
CAlv,NO 3.9 (2.5e5.3) 2.7
J’aw,NO 53 (37e78) 26 (
Fe,NO 21 (15e32) 12 (
Positive bacterial culture NA NA
Use of ICS (%) 3% 0%
Data expressed as mean SD.
Exhaled NO data expressed as median (interquartile range).
% pred, percent predicted; L, liters; NA, not applicable; ICS, inhaledin COPD,10 it could be more interesting for COPD to look at
the fraction of exhaled NO that originates from lung
periphery instead of total exhaled NO.
Measuring eNO at multiple expiratory flows (MEFeNO)
can be used to segregate total exhaled NO into an alveolar
and airway fraction of eNO.11e14 In 2005, Brindicci et al.
demonstrated that COPD associated with elevated alveolar
NO levels15 but their findings could not be confirmed by
others.16 As commercial equipments are now distributed to
monitor the alveolar NO fraction, more validation studies
are required to investigate whether alveolar NO contrib-
utes to the diagnosis of COPD in a clinical setting. We
therefore investigated the use of alveolar NO and bronchial
NO in a group of ambulatory COPD patients of different
GOLD stages and compared it with an age-matched control
group.
Methods
Subjects
All study participants were recruited from the neighbor-
hood of Leuven (Belgium) via the service of Respiratory
Medicine at the University Hospital of Leuven. Consenting
patients had a smoking history of at least 15 pack-years and
a minimal age of 50 years. Patients with the suspected or
previous diagnosis of asthma were excluded as well as
patients with other respiratory diseases affecting pulmo-
nary function. Patients with established COPD were
recruited during stable clinical condition with at least 6
weeks from the last exacerbation. Smoking controls with
normal spirometry as well as patients with early non-
diagnosed COPD were obtained from a patient cohort fol-
lowed at our service in the context of a Dutch-Belgian
randomized lung cancer screening trial (NELSON). Here,
COPD was diagnosed according to the Global Initiative
for Obstructive Lung Disease (GOLD) definition (post-lthy smokers COPD ex-smokers COPD smokers
55 29
 5 65 6 63 5
69% 93%
 4 24 5 26 5
2/12/27/14 10/14/4/1
 23 50 25 58 23
 0.7 1.2 0.5 2.2 0.9
 14 45 17 69 22
 0.9 2.9 0.8 3.9 1.0
 18 85 20 97 17
 4 41 12 55 12
(1.5e4.6) 3.4 (2.3e5.8) 2.6 (1.7e3.0)
19e43) 35 (23e70) 20 (14e35)
8e18) 15 (10e25) 10 (7e13)
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85% 41%
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Figure 1 Concentrations of alveolar nitric oxide (CAlv,NO)
(a), airway nitric oxide (J’aw,NO) (b) and fractional exhaled NO
(Fe,NO) (c) in chronic obstructive pulmonary disease patients
and healthy subject.
1022 A. Lehouck et al.bronchodilator forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) ratio below 0.7). From
this cohort, healthy smokers were selected to obtain an
age-matched control group and subsequently, cases and
controls were stratified according to current or ex-smoking
behavior. One-hundred and fifty-one patients were studied
of which 84 were COPD patients (55 ex-smokers and 29
smokers) and 67 were healthy control subjects (28 ex-
smokers and 39 smokers). According to the GOLD criteria,
12 patients presented with GOLD stage 1 (FEV1 %pred>
80%), 26 with GOLD stage 2 (80%> FEV1 %pred> 50%), 31
with GOLD stage 3 (50%> FEV1 %pred> 30%) and 15 with
GOLD stage 4 (FEV1 % pred< 30%). The study was approved
by the Institutional Review Board (Ethical Committee
UZ-Leuven) and all subjects gave informed consent before
participation. The demographic features of the subjects
are shown in Table 1.NO measurements
NO measurements were preformed between 9 and 12am.
Exhaled NO was measured by a chemiluminescence analyzer
(NIOX Flex; Aerocrine AB, Stockholm, Sweden) that was
calibrated every 14 days. NO free air was inhaled to total
lung capacity and patients exhaled against a constant flow
rate. Exhaled NO was measured at flow rates of 50, 100 and
200 ml/s. For each flow rate we used the mean value of two
measurements. Single exhaled NO fraction (Fe,NO) was
measured at a flow rate of 50 ml/s. A mathematical
approach based on a two-compartment model initially
designed by Tsoukias et al.17 and recently improved by
Condorelli et al.18 was then used to differentiate between
NO generated in the airways and NO generated in the alveoli.
Briefly, CAlv,NO (ppb) and maximal bronchial output of NO
(J’aw,NO; nL/min) were estimated as follows:
CAlv,NOZ S I ((0.001 s/mL)/(0.53)); and J’aw,NOZ (I/
0.53) 0.06; where S is the slope and I is the y-intercept of
the linear regression over the NO output versus the flow rate.
Lung function
Spirometry, lung volumina and diffusing capacity were
measured by means of body plethysmography using stan-
dard methodology.19 All pulmonary function measurements
were performed with standardized equipments (Acertys,
SensorMedics, Belgium) according to ATS/ERS guidelines
and absolute values were expressed as percent predicted of
reference values.20 Because of the known effect of spiro-
metric maneuvers and exercise on exhaled NO, we per-
formed NO measurements prior to lung function.21
CRP measurements
Serum C-reactive protein (CRP) levels were measured via an
immunoturbidimetric assay on a Modular analyzer (Roche
Diagnostics).
Quantitative bacterial cultures
In the subgroup of COPD patients, a spontaneous morning
sputum sample was collected. All patients were carefully
instructed to blow their noses and rinse their mouths with
water and were provided with a cooling box to transport
the sample. Processing of sputum samples and quantifica-
tion of potential pathogens was preformed as described by
Sethi et al.22
Statistical methods
The significance of difference between two groups was
assessed with a two-tailed ManneWhitney test (t-test). The
difference between multiple groups was evaluated with the
nonparametric KruskaleWallis test (ANOVA) with Dunn post-
test. Correlation of Fe,NO, CAlv,NO and J’aw,NO with
numerous variables was assessed with simple regression and
withmultiple regression. Ap-value below0.05was considered
as significant. Because of their nonparametric nature, data
wereexpressedasmedianand interquartile ranges. Statistical
analysis was performed with GraphPad Prism 4 and SAS 9.1.
Table 2 Demographics of the Nelson cohort.
Healthy ex-smokers Healthy smokers COPD ex-smokers COPD smokers
Subjects 28 39 5 19
Age (years) 63 5 63 5 65 7 62 5
Gender (% male) 93% 77% 80% 95%
BMI 27 3 27 4 29 5 27 5
GOLD (1/2/3/4) NA NA 1/4/0/0 10/9/0/0
Pack year history 47 27 45 23 45 11 62 25
FEV1 (L) 3.3 0.6 3.1 0.7 2.2 0.6 2.6 0.7
FEV1 (% pred) 101 15 100 14 71 11 81 16
FVC (L) 4.4 0.8 4.1 0.9 3.5 1.0 4.3 0.9
FVC (% pred) 110 15 110 18 93 13 103 17
FEV1/FVC (% pred) 73 3 73 4 60 5 62 8
CAlv,NO 3.9 (2.5e5.3) 2.7 (1.5e4.6) 4.0 (3.1e6.7) 2.8 (1.9e3.3)
J’aw,NO 53 (37e78) 26 (19e43) 83 (47e89) 23 (19e36)
Fe,NO 21 (15e32) 12 (8e18) 22 (18e31) 10 (9e14)
Use of ICS (%) 3% 0% 0% 16%
Data expressed as mean SD.
Exhaled NO data expressed as median (interquartile range).
% pred, percent predicted; L, liters; NA, not applicable.
Alveolar exhaled NO in COPD 1023Results
NO measurements in COPD patients and control
subjects
No significant difference could be observed in CAlv,NO
between COPD patients and age-matched healthy controls.
When stratifying healthy controls and COPD patients in
smoking and ex-smoking subgroups, we found that in both
COPD patients and healthy controls, the active smoking
status significantly reduced median CAlv,NO (Fig. 1a)
(p< 0.05). Similar results were found for Fe,NO and
J’aw,NO, which median values were not significantly
different between COPD and healthy controls but which
were also found to be significantly determined by current
smoking status (Fig. 1b, c). When focusing on the subgroup
of patients with no former diagnosis of COPD (Nelson
cohort; Table 2), neither CAlv,NO, Fe,NO or J’aw,NO was
found to be significantly different between the patients
with a post-bronchodilator FEV1/FVC ratio below or
above 0.7.
NO measurements in COPD patients according to
disease severity
As none of the exhaled NO tests was able to discriminate
between absence or presence of COPD, we then investi-
gated whether CAlv,NO, Fe,NO and J’aw,NO were different
according to severity of the disease. A non-adjusted
comparison in COPD patients, between the different GOLD
stages, could not reveal any statistical significant differ-
ence of median CAlv,NO, Fe,NO and J’aw,NO (Fig. 2aec) In
addition, a crude analysis demonstrated no significant
correlation between FEV1 and any of the exhaled NO vari-
ables (p_CAlv,NOZ 0.82; p_J’aw,NOZ 0.56; p_Fe,NOZ
0.57). Moreover, when adjusting for confounders such as
age, gender, current smoking behavior and BMI, no signifi-
cant relationship between FEV1 and exhaled NO could beretained. No associations were found between exhaled NO
variables and serum CRP or presence of bacteria in morning
sputa. Similar analyses were done with DLCO and KCO as
surrogate markers for emphysema, but again no significant
associations could be found with crude and adjusted
models (data not shown).
Effect of current smoking behavior, inhaled
corticosteroids (ICS) and age on NO measurements
Current smoking behavior was a constant confounder in the
associations between all exhaled NO measurements,
including CAlv,NO. When focusing on the differences
between obstructive ex-smokers and healthy ex-smokers,
no significant difference in all the exhaled NO measure-
ments could be seen. When stratifying for the use of ICS in
the COPD population (39 % of patients used ICS), no
significant difference could be seen on any of the different
exhaled NO variables (Fe,NO, CAlv,NO, J’aw,NO) over the
different GOLD stages (data not shown). No correlation was
present between exhaled NO measurements and age.
Variability over time
In a random subgroup of 22 COPD patients, Fe,NO, CAlv,NO
and J’aw,NO was assessed 4 months after the first
measurement, to examine variability over time. CAlv,NO
and J’aw,NO results were not significantly different
between the first and second visit 4 months later (Fig. 3a
and b). On the other hand, we did find a significant
difference between measurements of Fe,NO between these
same time points (pZ 0.023; Fig. 3c).
Discussion
We performed in 151 smoking or former smoking individuals
exhaled NO measurements at different flow rates and found
that neither Fe,NO, CAlv,NO and J’aw,NO was able to
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Figure 2 Concentrations of alveolar nitric oxide (CAlv,NO)
(a), airway nitric oxide (J’aw,NO) (b) and fractional exhaled NO
(Fe,NO) (c) in chronic obstructive pulmonary disease patients
of different severity according to the classification of the
Global Initiative for chronic obstructive lung disease (GOLD).
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Figure 3 Variation of concentrations of alveolar nitric oxide
(CAlv,NO) (a), airway nitric oxide (J’aw,NO) (b) and fractional
exhaled NO (Fe,NO) (c) between the first visit and a second
visit, 4 months later (visit 2).
1024 A. Lehouck et al.differentiate COPD from healthy controls in a caseecontrol
design. In addition, we could not find any association
between disease severity as assessed by GOLD stage or FEV1
and exhaled NO variables (Fe,NO, CAlv,NO, J’aw,NO) in the
COPD group.
With regard to our findings on Fe,NO, the present results
are not surprising as many different articles have demon-
strated conflicting data on this subject in the past.23,24 The
use of CAlv,NO and J’aw,NO, however, is relatively new and
so far only two different groups have investigated its
potential role in COPD. Brindicci et al. were the first to
report that CAlv,NO was significantly higher in COPD
patients. They also claimed that CAlv,NO was associated
with severity of disease15 although their data were
hampered by a limited number of patients and the use ofa control group which was not matched for age. Indeed, Roy
et al. could not confirm the Brindicci findings in a larger
patient sample of 50 COPD subjects and 90 age-matched
controls but because most of their patients had mild to
moderate disease, the authors were unable to evaluate
whether alveolar NO related to disease severity. The
present study however, investigates different exhaled NO
markers in COPD patients of the different GOLD stages and
compares them with a proper age-matched control group
with similar smoking history. Similar to the observations of
Roy et al.,16 we found that when differentiating exhaled NO
variables into Fe,NO, CAlv,NO and J’aw,NO fractions, these
variables did not associate with the severity of the disease
according to GOLD. In addition, increased CRP or bacterial
presence in morning sputa of COPD patients which may also
reflect disease severity differently from FEV1, did not
correlate with any of the exhaled NO biomarkers. Moreover,
when restricting the analysis to a subgroup of patients at
risk for COPD but with no diagnosis in the past, none of the
Alveolar exhaled NO in COPD 1025variables could reliably distinguish newly diagnosed COPD
patients from healthy controls.
Because we used a proper age-matched control group
and because the variation of age in our COPD population
was rather limited, our results were not affected by age.
The use of ICS did also not influence our results. However,
and in contrast with previous data, CAlv,NO was signifi-
cantly reduced by the present smoking status.15,16 Finally,
when correcting for axial diffusion, a significant correlation
between CAlv,NO and J’aw,NO (p< 0.001) was still present,
suggesting at least that both fractions may influence each
other and that strict separation between bronchial and
alveolar fractions was difficult to obtain.
Overall, the value of different exhaled NO variables in
the diagnostic work-up of COPD patients who often smoke
before assessment, becomes questionable. The technique
and software to determine the different NO fractions is
commercially available by now but, supported by our data,
we think that similar to single breath exhaled NO, alveolar
and airway exhaled NO will not be useful in the clinical
routine of COPD. Although the previously reported differ-
ences on alveolar NO might be significant in optimal labo-
ratory conditions and a selected subgroup of patients,15 the
widespread use of this technique will be rather flawed.
This study has some potential limitations. First, exhaled
NO measurements are stated as reproducible, but are
dependent of several factors apart from smoking and age.
Factors which may increase exhaled NO levels are viral
infections, allergic airway inflammation and recent intake
of nitrate-rich diets, whereas spirometry, bronchocon-
striction and exercise may lead to a reduction of exhaled
NO.21,25e29 Although asthma patients were excluded and
although all patients were in stable clinical condition at the
time of the test, which was performed prior to spirometry,
we did not assess the intake of nitrate-rich diet. In addi-
tion, patients were not instructed to stop smoking 12 h on
beforehand, as the purpose of this study was to evaluate
the potential of this technique in a daily respiratory prac-
tice. Moreover, evaluation of NO measurements in the
ex-smoking individuals did not show any difference either.
Secondly, CAlv,NO is known to be highly variable and
extremely model-dependent. It has been stated that the
use of five flow rates is more reliable than data from four or
three flow rates.16 Our main motive to use three flow rates
was to apply a method that could be completed by most of
the COPD patients with regard to the clinical relevance. For
instance, the study of Roy and colleagues had to exclude
35% of the patients because they were unable to perform
acceptable exhaled NO measurements at very low and
higher flow rates.16 In our study, we only excluded 6% of the
patients for similar reasons. We think that the choice of
exhalation flow rates of 50, 100 and 200 ml/s respectively,
is fair as these flows are situated in the linear domain of the
relationship between the elimination rate of NO and flow
rates of exhalation.30 Finally, we did not exclude patients
in whom linearity between the three exhaled NO
measurements was relatively poor, to avoid selection bias
towards an optimal laboratory setting far from clinical
reality. But, when using a 0.5 cut-off for R-square to define
acceptable linearity between NO output and expiratory
flow, similar results were obtained in the remaining pop-
ulation (nZ 142).Conclusion
Our data oppose against the use of CAlv,NO, J’aw,NO and
Fe,NO in the diagnosis and phenotypic description of COPD
in a clinical setting. Future research in COPD needs to focus
on other biomarkers than exhaled NO.
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